Skip to main content
. 2017 Aug 12;8(47):83088–83099. doi: 10.18632/oncotarget.20236

Figure 1. Analysis of CAIX RNA expression in The Cancer Genome Atlas (TCGA) microarray data set.

Figure 1

(A) Analyses of CAIX expression in all types of cancer in TCGA microarray data set. UCEC, uterine corpus endometrial carcinoma; THCA, thyroid carcinoma; STES, stomach and esophageal carcinoma; STAD, stomach adenocarcinoma; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma; LIHC, liver hepatocellular carcinoma; KIRC, kidney renal clear cell carcinoma; KIPAN, pan-kidney cohort (kidney chromophobe + KIRC + kidney renal papillary cell carcinoma); HNSC, head and neck squamous cell carcinoma; ESCA, esophageal carcinoma; BRCA, breast invasive carcinoma; BLCA, bladder urothelial carcinoma. (B) Analyses of CAIX expression in normal oral tissues (n = 33) and oral tumors (n = 328) in TCGA microarray data set. (C) Analyses of CAIX expression in 33 pairs of normal and tumor oral tissues in TCGA microarray data set. (D) Analyses of CAIX expression in 303 patients with oral cancer in TCGA microarray data set. (E) Effect of CAIX expression on the overall survival of 298 patients with oral cancer evaluated using the Kaplan–Meier method.